EFFECTS OF HTD1801 (BERBERINE URSODEOXYCHOLATE) ON THE GUT MICROBIOTA IN THREE RODENT MODELS OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES

被引：0
|
作者：
Bai, Ru [1 ]
Yu, Meng [1 ]
Liu, Liping [1 ]
Di Bisceglie, Adrian M. [1 ]
机构：
[1] Hightide Therapeut, Shenzhen, Peoples R China
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4301
引用
收藏
页码：S1288 / S1288
页数：1
相关论文
共 50 条
  • [1] EFFECTS OF HTD1801 (BERBERINE URSODEOXYCHOLATE) ON NON-INVASIVE FIBROSIS MARKERS IN SUBJECTS WITH PRESUMED NASH AND TYPE 2 DIABETES
    Harrison, Stephen A.
    Gunn, Nadege
    Neff, Guy W.
    MacConell, Leigh
    Loomba, Rohit
    HEPATOLOGY, 2021, 74 : 1136A - 1137A
  • [2] Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus
    Harrison, Stephen
    Gunn, Nadege
    Neff, Guy
    Flyer, Abbey
    Liberman, Alexander
    MacConell, Leigh
    JOURNAL OF HEPATOLOGY, 2023, 78 : S653 - S654
  • [3] Berberine Ursodeoxycholate (HTD1801) Improves Key Glycemic and Cardiometabolic Parameters across the Type 2 Diabetes Mellitus Disease Spectrum
    Ji, Linong
    Ma, Jianhua
    Ma, Yujin
    Cheng, Zhifeng
    Gan, Shenglian
    Yuan, Guoyue
    Liu, Dexue
    Li, Sheli
    Liu, Yu
    Xue, Xia
    Bai, Jie
    Wang, Kun
    Cai, Hanqing
    Li, Shu
    Liu, Kui
    Yu, Meng
    Liu, Liping
    DIABETES, 2024, 73
  • [4] Gut microbiota and non-alcoholic fatty liver disease
    Gkolfakis, Paraskevas
    Dimitriadis, George
    Triantafyllou, Konstantinos
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2015, 14 (06) : 572 - 581
  • [5] Gut microbiota and non-alcoholic fatty liver disease
    Abenavoli, Ludovico
    Procopio, Anna C.
    Scarpellini, Emidio
    Polimeni, Natale
    Aquila, Isabella
    Larussa, Tiziana
    Boccuto, Luigi
    Luzza, Francesco
    MINERVA GASTROENTEROLOGY, 2021, 67 (04): : 339 - 347
  • [6] Gut microbiota and non-alcoholic fatty liver disease
    Paraskevas Gkolfakis
    George Dimitriadis
    Konstantinos Triantafyllou
    Hepatobiliary&PancreaticDiseasesInternational, 2015, 14 (06) : 572 - 581
  • [7] A randomized, double blind, placebo-controlled trial of htd1801 (berberine ursodeoxycholate, budc) in patients with hypercholesterolemia: implications for its use in non-alcoholic steatohepatitis (NASH)
    Di Bisceglie, Adrian
    Watts, Gerald
    Linberg, Bao-Van
    Yu, Li
    Yu, Meng
    Lavin, Philip
    Liu, Liping
    JOURNAL OF HEPATOLOGY, 2020, 73 : S440 - S441
  • [8] Non-alcoholic fatty liver and the gut microbiota
    Bashiardes, Stavros
    Shapiro, Hagit
    Rozin, Shachar
    Shibolet, Oren
    Elinav, Eran
    MOLECULAR METABOLISM, 2016, 5 (09): : 782 - 794
  • [9] Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease
    Koukias, Nikolaos
    Buzzetti, Elena
    Tsochatzis, Emmanuel A.
    MINERVA ENDOCRINOLOGICA, 2017, 42 (02) : 184 - 194
  • [10] Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease
    Zhou, Jin
    Tripathi, Madhulika
    Sinha, Rohit A.
    Singh, Brijesh Kumar
    Yen, Paul M.
    HEPATOMA RESEARCH, 2021, 7
12345